Clusterin, also known as apoJ, is a lipoprotein abundantly expressed within the CNS. It regulates Ab fibril formation and toxicity and facilitates amyloid-b (Ab) transport across the blood-brain barrier. Genome-wide association studies have shown variations in the clusterin gene (CLU) to influence the risk of developing sporadic Alzheimer's disease (AD). To explore whether clusterin modulates the regional deposition of Ab, we measured levels of soluble (NP40-extracted) and insoluble (guanidine-HCl-extracted) clusterin, Ab40 and Ab42 by sandwich ELISA in brain regions with a predilection for amyloid pathology-mid-frontal cortex (MF), cingulate cortex (CC), parahippocampal cortex (PH), and regions with little or no pathology-thalamus (TH) and white matter (WM). Clusterin level was highest in regions with plaque pathology (MF, CC, PH and PC), approximately mirroring the regional distribution of Ab. It was significantly higher in AD than controls, and correlated positively with Ab42 and insoluble Ab40. Soluble clusterin level rose significantly with severity of cerebral amyloid angiopathy, and in MF and PC regions was highest in APOE E4 homozygotes. In the TH and WM (areas with little amyloid pathology) clusterin was unaltered in AD and did not correlate with Ab level. There was a significant positive correlation between the concentration of clusterin and the regional levels of insoluble Ab42; however, the molar ratio of clusterin : Ab42 declined with insoluble Ab42 level in a region-dependent manner, being lowest in regions with predilection for Ab plaque pathology. Under physiological conditions, clusterin reduces aggregation and promotes clearance of Ab. Our findings indicate that in AD, clusterin increases, particularly in regions with most abundant Ab, but because the increase does not match the rising level of Ab42, the molar ratio of clusterin : Ab42 in those regions falls, probably contributing to Ab deposition within the tissue.
INTRODUCTION
Alzheimer's disease (AD) is believed to be initiated by the accumulation and aggregation of amyloid-b (Ab) peptides [the so-called amyloid cascade hypothesis (1) ]. The steady-state level of Ab reflects the balance between its production and removal from the brain (2) . Ab peptides are produced by sequential cleavage of Ab protein precursor (APP) and mostly end at amino acid 40 or 42. Ab42 is the more amyloidogenic form-relatively insoluble in the interstitial fluid and prone to parenchymal deposition. Ab40 is more soluble, less prone to parenchymal deposition but more likely to accumulate in the walls of cortical and leptomeningeal blood vessels (3, 4) . Most mutations in familial AD are associated with increased amyloidogenic processing of APP and elevated Ab42 or an increase in the Ab42 : Ab40 ratio (5) (6) (7) (8) . In sporadic AD, which accounts for most cases, the accumulation of Ab is thought largely to reflect alterations in the pathways responsible for the removal of Ab [reviewed in (2) ] or altered expression of chaperone proteins, such as apoE and clusterin (also known as apoJ) that regulate the structure, toxicity and clearance of Ab [reviewed in (9) ].
Ab peptides are produced throughout life (10, 11) but begin to accumulate and aggregate in the brain more than a decade before the onset of AD (12, 13) . Risk factors for AD, such as ageing and APOE genotype (14) , accelerate the parenchymal deposition of Ab. The deposition of Ab within the brain follows a hierarchical sequence first appearing in the neocortex and spreading to limbic areas, deep cerebral gray matter and brain stem regions and finally the cerebellum (15) . The determinants of regional variability in the susceptibility of different brain regions to Ab deposition remain unclear. No link was found between the distribution of plaque pathology and the regional distribution of enzymes involved in the amyloidogenic processing of APP (APP, APP-CRFB, BACE-1 and PS-1; (16) (17) (18) (19) ). However, Shinohara et al (19) found a strong inverse relationship between apolipoprotein E (apoE) level and Ab deposition in brain tissue from cognitively normal elderly people and those with mild cognitive impairment (MCI). The authors suggested that apoE had a role in preventing Ab accumulation and was reduced in brain regions that would later develop significant plaque pathology.
Clusterin, also known as apolipoprotein-J, is a 78-80 kDa heterodimeric glycoprotein that is abundantly expressed in the CNS (20) . Genome-wide association studies have identified several single nucleotide polymorphisms within the clusterin gene (CLU) that are risk factors for AD (21) (22) (23) (24) . Clusterin is up-regulated in the brain in AD (25, 26) and is present in plaques (27, 28) . In vitro studies suggest that clusterin influences Ab fibril formation and neurotoxicity (reviewed in (29, 30) ) and can facilitate the transport of Ab across the blood-brain barrier (31) . We have undertaken a comprehensive analysis of the regional distribution of clusterin, soluble and insoluble Ab40 and Ab42 in post-mortem brain tissue across a number of brain regions that vary in their predilection to amyloid pathology. Our findings indicate that clusterin level rises with the accumulation of insoluble Ab42 but the molar ratio of clusterin : Ab42 falls, which probably influences the regional distribution of Ab deposition.
MATERIALS AND METHODS

Case selection
Brain tissue was obtained from the South West Dementia Brain Bank (SWDBB), University of Bristol, UK with local research ethics committee approval. All brains had been retrieved within 72 h of death. The right cerebral hemisphere had been fixed in 10% formalin for three weeks before the tissue was processed and paraffin blocks were taken for pathological assessment. The left cerebral hemisphere had been sliced and frozen at 2808C until used for biochemical assessment. According to the NIA-AA guidelines AD neuropathological change was considered an adequate explanation for the dementia in all cases in the AD group (32) . Controls were defined by an absence of clinical history of cognitive decline or other neurological disease and a lack of neuropathological abnormalities apart from sparse neuritic or diffuse plaques in some of the older cases, all of which were of Braak tangle stage III or lower. APOE genotyping and assessment of severity of cerebral amyloid angiopathy (CAA) had been performed as previously reported (33, 34) . Demographic information, neuropathological findings and MRC identifiers for each case are shown in Supporting Information Tables S1 and S2.b
Brain tissue
Brain tissue (200 mg) was dissected from the midfrontal, cingulate, parahippocampal and medial parietal cortex, thalamus (pulvinar) and white matter (WM) underlying the parietal cortex. Brain tissue samples were prepared using a Precellys 24 homogenizer (Stretton Scientific, Derbyshire, UK) with 2.3 mm ceramic beads (Biospec, Stratech, Suffolk, UK) as previously described for Ab measurements in human postmortem tissue (10, 11, 35, 36) . Soluble and insoluble extracts were prepared sequentially following initial homogenization in 1% NP-40 buffer containing 140 mM NaCl, 3 mM KCl, 25 mM TRIS, 5 mM ethylenediaminetetraacetic acid (EDTA) and 2 mM 1,10 phenanthroline). The homogenates were spun at 13 000 3 g for 15 min at 48C and the supernatant was removed and stored at 2808C. Insoluble extracts were prepared by homogenization of pelleted insoluble material in 6 M GuHCl and were left for 4 h at room temperature (RT) before storage at 2808C.
Measurement of clusterin levels by sandwich ELISA
Clusterin level was measured by sandwich ELISA (duoset kit # DY5874, R&D systems, Oxford, UK) according to the manufacturer's guidelines; 96-well Maxisorp plates (R&D systems, Oxford, UK) were coated at RT overnight with mouse anti-human clusterin. We washed the plates in phosphate-buffered saline (PBS)/tween-20 (0.01%), added 1% PBS/BSA at RT for 1 h to block nonspecific binding, then added recombinant human clusterin (62.5-4000 pg/ mL) and tissue homogenates (2.5 lL supernatant diluted in 3.125 mL PBS, and 1.8 lL insoluble extract diluted in 10 mL PBS) for 2 h at RT. After a further wash, the plate was incubated for 2 h at RT with biotinylated mouse anti-human clusterin. The plate was again washed and incubated with streptavidin-horseradish peroxidase (HRP; 1:200 in 0.01% PBS : Tween-20) for 20 minute at RT in the dark, washed, and incubated for 10 minute with chromogenic substrate (TMBS, R&D systems, Oxford, UK). Absorbance was read at 450 nM in a FLUOstar Optima plate reader (BMG Labtech, Ayelsbury, UK) after the addition of 50 lL of 2 N sulfuric acid. Measurements were repeated in duplicate and across two plates to ensure that there was minimal plate-to-plate variation.
Measurement of Ab40 and Ab42 by sandwich ELISA
We measured Ab40 and Ab42 level in both soluble (NP1-40) and insoluble (guanidine-HCl-extracted) brain tissue fractions by sandwich ELISA as previously described (10, 11, (34) (35) (36) (37) (38) (39) . For the Ab40 ELISA, mouse monoclonal anti-human Ab (clone 6E10, raised against amino acids 1-16; Covance, Harrogate, UK), 2 mg/ mL in PBS, was incubated overnight at RT, washed and then blocked with 300 mL protein-free PBS blocking buffer (Thermo Fisher Scientific, Loughborough, UK) for 2 h at RT. Samples of brain homogenate (diluted 1:49 for guanidine extracts and 1:3 for soluble extracts) or recombinant human Ab1-40 (Sigma Aldrich, Dorset, UK) diluted in PBS containing 1% 1,10 phenanthroline (Sigma Aldrich, Dorset, UK) to prevent degradation of Ab (40), were incubated for 2 h at RT on a rocking platform. After a further wash, the plates were incubated for 2 h at RT with mouse antihuman Ab1-40 (1 mg/mL; 11A50-B10; Covance, Harrogate, UK) that had been biotinylated using Lightning-Link Biotinylation Kit (Innova Biosciences, Cambridge, UK) according to the manufacturer's guidelines. Streptavidin-HRP (R&D Systems Europe, Abingdon, UK) diluted 1:200 was added to each well for 20 min at RT before they were washed and substrate solution (TMB; R&D Systems Europe, Abingdon, UK) was added for 30 min in the dark. The reaction was stopped with 2N sulfuric acid (R&D Systems Europe, Abingdon, UK) and the optical density of each well read at 450 nm in a FLUOstar plate reader (BMG Labtech, Aylesbury, UK).
For the Ab42 ELISA, anti-human Ab1-42 (12 F4, Covance) diluted 0.5 lg/mL in PBS was used as the capture antibody. Tissue samples (insoluble extracts diluted 1:9, soluble extracts diluted 1:3) were incubated at RT for 4 h. Biotinylated anti-human Ab (Thermo Fisher Scientific) diluted to 0.1 lg/mL in PBS was used for detection and left overnight at 48C. After washing, streptavidin-HRP was added for 1 h and chromogenic substrate for 20 min in the dark after a further wash. Ab1-42 concentration in brain tissue was interpolated from a standard curve generated by serial dilution (16 000 to 1.024 nM) of recombinant human Ab1-42 (Sigma Aldrich). Each sample was assayed in duplicate. The Ab1-42 ELISA did not detect Ab1-40, and the Ab1-40 ELISA did not detect Ab1-42.
Statistical analysis
Unpaired two-tailed t-test or ANOVA with Dunnett's post hoc analysis was used for comparisons between groups, and Pearson's or Spearman's test was used to assess linear or rank order correlation, as appropriate, with the help of SPSS version 16 (SPSS, Chicago) and GraphPad Prism version 6 (GraphPad Software, La Jolla, CA). P-values < 0.05 were considered statistically significant.
RESULTS
Regional distribution of soluble and insoluble Ab40 and Ab42 in AD
We examined the regional distribution of soluble (NP-40-soluble) and insoluble (after guanidine-HCl extraction) Ab40 and Ab42 in sequentially extracted brain homogenates from the following regions in AD and age-matched controls: midfrontal cortex (MF), cingulate cortex (CC), parahippocampal cortex (PH), medial parietal cortex (PC), thalamus (TH) and parietal WM (Figure 1 ). In CC, MF, PH and PC, the concentrations of insoluble Ab40 and Ab42 were significantly higher in AD than age-matched controls. The differences between AD and control brains in TH and WM did not reach significance.
In both control and AD groups, the concentration of insoluble Ab40 and Ab42 tended to decrease in the following order: CC > MF > PH > PC > TH and WM ( Figure 1A,B) . In AD, the concentration of insoluble Ab40 and Ab42 was significantly higher in neocortex (MF and CC) than in other regions ( Figure 1A,B) .
The regional distribution of soluble Ab40 and Ab42 differed substantially from that of insoluble Ab40 and Ab42. The concentration of the soluble forms of Ab was lowest in MF and CC and tended to be higher in PC, PH, TH and WM ( Figure 1C,D) . Soluble Ab level did not differ to a statistically significant extent between AD and controls, with the exception of increased Ab42 in AD within WM. In general the concentration of Ab in gray matter regions was much lower in the soluble than the insoluble tissue fractions. In contrast, Ab40 and Ab42 concentration was higher in the soluble than the insoluble tissue fractions of WM, and soluble Ab level was several-fold higher in WM than cortex. Soluble Ab42 level was also relatively high in PH.
The relative contribution of soluble and insoluble Ab40 and Ab42 to "total" Ab load in all regions studied is shown in Supporting Information Figure S1 . "Total" Ab was highest in MF and CC and tended to decrease in PH > PC > TH. Total Ab in MF and CC Figure 1 . Bar charts showing regional levels of Ab level in control (black bars) and AD brains (red bars), in MF, CC, PH, medial parietal cortex (PC), thalamus (TH) and parietal WM. Bars indicate the mean and SEM. *P < 0.05 **P < 0.01 ***P < 0.001 ****P < 0.0001. Lines indicate significant differences between regions, in the controls (black lines) and AD groups (red lines); the thickness of the line indicates the significance of the difference between the two regions, ranging from P < 0.01 to P < 0.0001. consisted almost entirely of insoluble Ab40 and Ab42. In contrast, in WM, most of the Ab consisted of soluble Ab40 with a small amount of insoluble Ab40 and negligible Ab42.
Regional distribution of clusterin in AD
We examined the regional distribution of clusterin in the same soluble and insoluble brain fractions in AD and age-matched controls that we had used to measure Ab levels ( Figure 2 ). In AD, clusterin level within both the soluble and insoluble extracts was highest in CC, MF and PH and PC and lowest in the TH and WM (approximately mirroring the regional distribution of "total" Ab). The level of soluble clusterin was less variable between regions in the controls but was significantly higher in CC than PC or TH ( Figure  2A ). Clusterin level in the insoluble extract was significantly higher in all gray matter regions than in the WM (Figure 2A) .
The level of soluble clusterin was significantly higher in AD than controls in most regions (CC, MF, PH and PC; Figure 2A ) and was increased in the insoluble extract in MF and PH ( Figure  2B ). Clusterin level within the soluble and insoluble extracts correlated significantly with soluble and insoluble Ab42 and Ab40 in MF (with the exception of insoluble Ab42; Table 1 ). A similar trend was observed between clusterin and Ab levels within the soluble extract in the PC but not the insoluble extract. A strong correlation was observed in the CC between clusterin and soluble and insoluble Ab40. There was less correlation between clusterin and Ab in the TH and WM (Table 1) .
Regional association of clusterin and ab
To assess whether variations in clusterin concentration might influence the regional distribution of soluble and insoluble Ab40 or Ab42, we looked at the correlation between Ab level and clusterin concentration across all regions. There was a significant correlation between the concentration of soluble clusterin and the level of insoluble Ab42 within the AD cohort and a weaker, nonsignificant trend in the controls ( Figure 3A,B) . A trend approaching significance was observed between clusterin in the insoluble extract and insoluble Ab42 in both controls and AD (Figure 3C,D) . We did not find significant correlations between clusterin concentration and the level of soluble Ab42, soluble Ab40 or insoluble Ab40.
To investigate further whether clusterin might promote the accumulation of insoluble Ab42, we calculated the molar ratio of insoluble clusterin to insoluble Ab42 in the different regions. In both controls and AD, the molar ratio of insoluble clusterin : insoluble Ab42 was lowest in regions with the highest concentration of insoluble Ab42 ( Figure 4A ,B) and vice versa.
Clusterin levels influenced by APOE genotype
Clusterin level was highest in APOE E4 homozygotes in MF and PC ( Figure 5 ) and rose significantly with severity of CAA. Posthoc analysis revealed significantly higher clusterin level in E4/4 than E3/3 brains in PC (P < 0.05), and in E4/4 than E3/4 (P < 0.01) or E3/3 (P < 0.05) in MF. Post-hoc analysis also showed clusterin level in MF and PC to be significantly higher in brains with severe than absent CAA (P < 0.05 for both regions). Insoluble clusterin level did not vary significantly in relation to APOE genotype or CAA severity.
DISCUSSION
We have examined the relationship between clusterin/apoJ level and the regional distribution of Ab within the brain. Although the concentration of clusterin was elevated in AD and was highest in cortical regions with the most abundant Ab deposition, the molar ratio of clusterin : Ab was lowest in those regions and was highest in parts of the brain with little or no amyloid pathology, such as in the thalamus and WM. These findings in human brain tissue support experimental studies indicating that (i) clusterin level rises in association with increasing Ab, (ii) within the physiological range of clusterin : Ab, clusterin reduces aggregation and promotes clearance of Ab, but (iii) when, despite a rise in clusterin, Ab level increases to an extent that causes clusterin : Ab to fall below the physiological range, Ab-clusterin complexes tend to aggregate and deposit within the brain parenchyma. We have also shown that clusterin concentration is influenced by APOE genotyope, being highest in brain tissue from E4 homozygotes, and rises in relation to the severity of CAA.
Clusterin is highly expressed in the CNS, within which it is present at a similar concentration to that of apoE (20) . Variations in the clusterin gene (CLU) are associated with sporadic AD (21), and previous studies showed that clusterin is increased in the CSF (41, 42) Figure 2 . Bar chart showing regional levels of clusterin level in control (black bars) and AD brains (red bars), in the soluble and insoluble brain tissue fractions. Bars indicate the mean and SEM. *P < 0.05 **P < 0.01 ***P < 0.001. Lines indicate significant differences between regions, in the controls (black lines) and AD groups (red lines); the thickness of the solid lines indicates the significance of the difference between the two regions, ranging from P < 0.01 to P < 0.0001. The interrupted horizontal lines indicate differences significant at the P < 0.5 level. and brain tissue (25, 26) in AD. Clusterin is detectable immunohistochemically within plaques (27, 28) and increases in association with neuritic plaque density (43) (44) (45) . In a transgenic APP/PS1 mouse model, clusterin level was elevated in plasma and brain tissue and found to co-localize with amyloid plaques (42) . Present findings show that the concentration of clusterin in human brain tissue in AD is highest in regions with the greatest concentration of Ab. Within those regions, clusterin concentration correlates closely with Ab level [as was also shown in transgenic mouse models of AD expressing mutant APP (46) ]. These findings are in keeping with clinical evidence of a correlation between raised plasma clusterin level and accelerated clinical progression of disease (41, 42) , and imaging studies showing that increased plasma clusterin levels were a strong predictor of brain amyloid load in AD patients (42) . Within subcortical regions that have a much lower level of Ab, clusterin concentration does not differ significantly between AD and controls.
In vitro studies indicate that clusterin binds to Ab and influences both fibril formation and toxicity (47, 48) . Yerbury et al (49) reported that clusterin coprecipitates with Ab as insoluble aggregates when Ab is present in large molar excess. We have found the molar ratio of clusterin : Ab42 to be lowest in regions that have the greatest accumulation of Ab (almost entirely in the insoluble tissue fraction) even though clusterin levels are highest in those regions. In contrast, within the WM and thalamus, which had the highest ratio of clusterin : Ab42, Ab was almost all in a soluble form. It seems that when the clusterin : Ab ratio falls low enough, clusterin actually promotes rather than simply fails to prevent the precipitation of Ab, as evidenced by in vitro data (49) . These data are consistent with experimental evidence in PDAPP mice (homozygous for the APP V717F transgene) showing that clusterin stimulates amyloid aggregation when Ab is present in excess. PDAPP mice homozygous for knock-out of the clusterin gene have significantly fewer fibrillar Ab deposits and dystrophic neurites than PDAPP mice expressing clusterin (50) . The rise in clusterin concentration that occurs with increasing Ab seems likely to be a consequence of the latter. Thamsbietty et al (42) reported that plasma clusterin level was elevated almost 10 years in advance of fibrillary Ab deposition, suggesting that clusterin production is raised at an early stage in the disease process, although we know from other studies that Ab starts to accumulate even earlier (51, 52) .
ApoE is also highly expressed within the CNS and has been implicated in the pathogenesis of AD. The APOE gene is a strong risk factor for sporadic AD and individuals possessing the E4 allele have more abundant plaque and cerebrovascular deposition of Ab and a higher level of this peptide (33, 34, 53) . In vitro studies demonstrated that apoE interacts with and influences Ab fibrillogenesis and clearance (54) (55) (56) (57) (58) . However, apoE and clusterin play somewhat divergent roles in the progression of AD. In contrast to clusterin, apoE concentration shows a strong inverse correlation with regional Ab load (19) , and while fibril formation was reduced in clusterin-deficient PDAPP mice (50) it was significantly increased in PDAPP mice deficient in both clusterin and apoE (59) . It is of interest that no regional association was found between Ab level and molecules involved in APP processing (APP, APP-CTFb, BACE-1 or PS-1) or enzymes involved in Ab clearance (neprilysin and insulin-degrading enzyme). Together, these data suggest that the regional distribution of Ab is influenced to a greater extent by apoE and clusterin expression than by pathways involved in the production or enzymatic degradation of Ab.
Clusterin has also been shown to facilitate the clearance of Ab at the blood-brain barrier (31) and is localized not only to plaques but also arterioles and capillaries within the brain (43) (44) (45) . A recent immunohistochemical study showed that clusterin was associated with vascular Ab, particularly Ab40, in CAA (60) . Co-localization of clusterin with perivascular Ab deposits and our finding of increased clusterin level in relation to CAA severity is supportive that elevation, the molar ratio of clusterin : Ab is lowest in those same regions, which is likely to influence the regional distribution of Ab by promoting its aggregation and precipitation.
